EZH2 and diffuse large B-cell lymphoma: Since EZH2 mutations in DLBCL and FL enhance EZH2 catalytic activity and EZH2 is essential for the development of GC B cells, EZH2 targeted therapy is a precision approach against GCB lymphomas.